Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Breast Cancer. 2016 Jun;19(2):214-217. English. Case Report. https://doi.org/10.4048/jbc.2016.19.2.214
Byun KD , Ahn SG , Baik HJ , Lee A , Bae KB , An MS , Kim KH , Shin JH , Park HK , Cho H , Jeong J , Kim TH .
Breast Center, Department of Surgery, Inje University Busan Paik Hospital, Busan, Korea. kitah@hanmail.net
Department of Surgery, Gangnam Medical Research Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Department of Radiation Oncology, Inje University Busan Paik Hospital, Busan, Korea.
Abstract

The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.

Copyright © 2019. Korean Association of Medical Journal Editors.